ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Modified Herpes Virus to Be Tested in Sarcoma Patients

OncLive
Published: Wednesday, Mar 09, 2011
The FDA has awarded a $600,000 grant for a phase I clinical trial of a genetically reprogrammed herpes simplex virus in young cancer patients with relapsed non-central nervous system (CNS) solid tumors such as sarcomas and neuroblastomas.The research involves potential uses for the HSV1716 virus, an “orphan drug” developed in Glasgow, Scotland, according to the Cincinnati Children’s Hospital Medical Center, Ohio. The institution announced in a press release that it has received the grant to study the virus. Certain genes have been removed from the HSV1716 so that the virus does not infect healthy dormant cells.

Researchers at the center are seeking to recruit 12 to 18 patients ≥13 years of age and ≤30 years whose oncologists have determined that there is no conventional or available therapy for them. The primary objective is to determine whether intratumoral injection of HSV1716, at dose levels shown to be safe for adult tumors, is also safe for adolescents and young adults with non-CNS solid tumors. Survival rates for these patients are generally <20%, the researchers indicated.

More Info» http://tiny.cc/qbz2c


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Publication Bottom Border
Border Publication
x